PBAC's latest decision on Trastuzumab emtansine: Recommended with restriction (2019). Considered for Adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease after pre-operative systemic treatment that included HER2-targeted therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
3
first 2013
Submissions
3
2013 → 2019
Eligible population
Patients with HER2-positive early breast cancer who have residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant therapy that included trastuzumab and taxane-based chemotherapy
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
KATHERINE
Comparator
trastuzumab
Economic model
CUA
ICER note
ICER value not stated in the provided text; economic analysis section appears to be cut off at Table 10 reference
Submission history
Jul 2013: Recommended with restriction · Authority Required
Mar 2014: Recommended with restriction · Authority Required
Nov 2019: Recommended with restriction · Authority Required